NASDAQ · VCEL
Healthcare · Biotechnology
$39.71
Up+$0.41 (+1.04%)
Updated Sep 27, 2026, 10:33 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
VCEL closed at $39.71 after 19 trading sessions, down 0.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $39.30 | $39.80 | $38.735 | $39.71 | 359.9K |
| Sep 24, 2026 | $38.86 | $39.40 | $38.385 | $39.30 | 351.98K |
| Sep 23, 2026 | $39.95 | $40.10 | $38.21 | $38.79 | 433.96K |
| Sep 22, 2026 | $40.00 | $40.4154 | $39.55 | $40.22 | 546.96K |
| Sep 21, 2026 | $40.08 | $40.29 | $39.05 | $39.55 | 402.18K |
| Sep 18, 2026 | $39.80 | $40.21 | $39.565 | $40.02 | 1.13M |
| Sep 17, 2026 | $40.62 | $40.62 | $39.06 | $40.03 | 536.42K |
| Sep 16, 2026 | $39.73 | $40.87 | $39.725 | $40.21 | 490.48K |
| Sep 15, 2026 | $39.39 | $40.145 | $38.545 | $39.72 | 654.83K |
| Sep 14, 2026 | $38.58 | $39.70 | $38.20 | $39.60 | 629.43K |
| Sep 11, 2026 | $38.39 | $38.945 | $37.35 | $38.34 | 503.53K |
| Sep 10, 2026 | $38.56 | $38.815 | $37.672 | $37.87 | 340.24K |
| Sep 9, 2026 | $38.72 | $39.19 | $38.53 | $38.99 | 366.52K |
| Sep 8, 2026 | $39.69 | $39.72 | $38.74 | $39.08 | 410.3K |
| Sep 4, 2026 | $40.04 | $40.57 | $39.85 | $40.19 | 312.91K |
| Sep 3, 2026 | $41.30 | $41.30 | $40.085 | $40.47 | 301.27K |
| Sep 2, 2026 | $40.49 | $41.49 | $40.35 | $40.89 | 395.53K |
| Sep 1, 2026 | $39.87 | $41.435 | $39.655 | $40.50 | 651.11K |
| Aug 31, 2026 | $40.48 | $40.8808 | $39.34 | $39.90 | 636.31K |
The latest Smart Investors Daily articles mentioning VCEL.
VCEL research
Company profile and research snapshot.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 28, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Vericel Corporation (VCEL) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 2:35 PM EDTCompany ParticipantsDominick C.
SeekingAlpha · Sep 14, 2026
Vericel stock outlook: MACI growth, expanded Burlington capacity, BARDA burn-care support, and pipeline catalystsâsee why bulls call VCEL a Buy despite premium.
Yahoo · Sep 8, 2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel CorporationVericel is
ChartMill · Sep 5, 2026
VERICEL CORP (VCEL) fits the Affordable Growth screen with high growth/profitability scores and valuation reasonable relative to biotech peers.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VCEL.
